There are many risks involved with opening pharmaceutical manufacturing operations in Asia, but Signapore has become ideal for the Life Sciences industry.
In an effort to bring patient awareness to available clinical trials, Shire, a biopharmaceutical company, uses mobile health to reach potential patients.
Even though there are 50.5 million know Hispanics in the U.S., ethnic diversity of clinical trial participants are limited for many reasons.
More and more drug companies are finding it financially advantageous to conduct clinical trials in foreign countries and to include data from these trials in NDA submissions. When offshore trials are properly conducted and the data is properly handled, this strategy can accelerate approval and lower the cost of drug development. By Ken Phelps, Camargo Pharmaceutical Services
Every biopharmaceutical company today is striving to arrive at the Proof-of-Concept decision point for new treatments as quickly and cheaply as possible. Management is looking to identify potential winners and avoid costly late stage failures. By Sy Pretorius, Corporate Vice President and World-wide Head of Early Phase, PAREXEL International Corporation
For industry committed to delivering innovative healthcare, now is the time to take stock of the shift in population demographics and how cultural competence relates to developing new medicines through clinical trials. By James Gillespie and Kathleen Drennan
The field of clinical research starts and ends with the patient volunteer. Unfortunately, there is a paucity of research volunteers for participation in clinical trials. Patient volunteers are increasingly scarce and even more limited when it comes to minority patient participation in clinical research trials. By Ruthie Barreau
|
|
|
|
|
|
|
|
|